These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 37956532)

  • 1. Mitochondrial adaptation decreases drug sensitivity of persistent triple negative breast cancer cells surviving combinatory and sequential chemotherapy.
    Winter M; Nait Eldjoudi A; Guette C; Hondermarck H; Bourette RP; Fovez Q; Laine W; Ghesquiere B; Adriaenssens E; Kluza J; Le Bourhis X
    Neoplasia; 2023 Dec; 46():100949. PubMed ID: 37956532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondrial structure and function adaptation in residual triple negative breast cancer cells surviving chemotherapy treatment.
    Baek ML; Lee J; Pendleton KE; Berner MJ; Goff EB; Tan L; Martinez SA; Mahmud I; Wang T; Meyer MD; Lim B; Barrish JP; Porter W; Lorenzi PL; Echeverria GV
    Oncogene; 2023 Mar; 42(14):1117-1131. PubMed ID: 36813854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vimentin Promotes the Aggressiveness of Triple Negative Breast Cancer Cells Surviving Chemotherapeutic Treatment.
    Winter M; Meignan S; Völkel P; Angrand PO; Chopin V; Bidan N; Toillon RA; Adriaenssens E; Lagadec C; Le Bourhis X
    Cells; 2021 Jun; 10(6):. PubMed ID: 34203746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.
    Desroys du Roure P; Lajoie L; Mallavialle A; Alcaraz LB; Mansouri H; Fenou L; Garambois V; Rubio L; David T; Coenon L; Boissière-Michot F; Chateau MC; Ngo G; Jarlier M; Villalba M; Martineau P; Laurent-Matha V; Roger P; Guiu S; Chardès T; Gros L; Liaudet-Coopman E
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38290768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic Response of Triple-Negative Breast Cancer to Folate Restriction.
    Coleman MF; O'Flanagan CH; Pfeil AJ; Chen X; Pearce JB; Sumner S; Krupenko SA; Hursting SD
    Nutrients; 2021 May; 13(5):. PubMed ID: 34068120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer.
    Singleton DC; Dechaume AL; Murray PM; Katt WP; Baguley BC; Leung EY
    BMC Cancer; 2020 May; 20(1):470. PubMed ID: 32450839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Energy Metabolism Drugs Block Triple Negative Breast Metastatic Cancer Cell Phenotype.
    Pacheco-Velázquez SC; Robledo-Cadena DX; Hernández-Reséndiz I; Gallardo-Pérez JC; Moreno-Sánchez R; Rodríguez-Enríquez S
    Mol Pharm; 2018 Jun; 15(6):2151-2164. PubMed ID: 29746779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-throughput, Label-Free Quantitative Proteomic Studies of the Anticancer Effects of Electrical Pulses with Turmeric Silver Nanoparticles: an in vitro Model Study.
    Mittal L; Camarillo IG; Varadarajan GS; Srinivasan H; Aryal UK; Sundararajan R
    Sci Rep; 2020 Apr; 10(1):7258. PubMed ID: 32350346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination Organelle Mitochondrial Endoplasmic Reticulum Therapy (COMET) for Multidrug Resistant Breast Cancer.
    Milane LS; Dolare S; Ren G; Amiji M
    J Control Release; 2023 Nov; 363():435-451. PubMed ID: 37717658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1-Chromonyl-5-Imidazolylpentadienone Demonstrates Anti-Cancer Action against TNBC and Exhibits Synergism with Paclitaxel.
    Modi K; Lawson S; Chen G; Tumuluri D; Rekhtman I; Kurtz M; Brailoiu GC; Chen QH; Lakshmikuttyamma A
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32806551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
    Tian J; Chen X; Fu S; Zhang R; Pan L; Cao Y; Wu X; Xiao H; Lin HJ; Lo HW; Zhang Y; Lin J
    Breast Cancer Res Treat; 2019 Jun; 175(3):553-566. PubMed ID: 30852762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination Treatment Using Pyruvate Kinase M2 Inhibitors for the Sensitization of High Density Triple-negative Breast Cancer Cells.
    Lee JS; Oh Y; Lee JS; Park JH; Shin JK; Han JH; Kim HS; Yoon S
    In Vivo; 2022; 36(5):2105-2115. PubMed ID: 36099094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial dynamics as a novel treatment strategy for triple-negative breast cancer.
    Wang Y; Harada-Shoji N; Kitamura N; Yamazaki Y; Ebata A; Amari M; Watanabe M; Miyashita M; Tada H; Abe T; Suzuki T; Gonda K; Ishida T
    Cancer Med; 2024 Jan; 13(2):e6987. PubMed ID: 38334464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway.
    Liu M; Yang J; Lv W; Wang S; Du T; Zhang K; Wu Y; Feng X
    Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34935899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
    Speyer CL; Bukhsh MA; Jafry WS; Sexton RE; Bandyopadhyay S; Gorski DH
    Breast Cancer Res Treat; 2017 Nov; 166(2):407-419. PubMed ID: 28780701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptome Profile Analysis of Triple-Negative Breast Cancer Cells in Response to a Novel Cytostatic Tetrahydroisoquinoline Compared to Paclitaxel.
    Gangapuram M; Mazzio EA; Redda KK; Soliman KFA
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low Dose of Paclitaxel Combined with XAV939 Attenuates Metastasis, Angiogenesis and Growth in Breast Cancer by Suppressing Wnt Signaling.
    Shetti D; Zhang B; Fan C; Mo C; Lee BH; Wei K
    Cells; 2019 Aug; 8(8):. PubMed ID: 31416135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells.
    Panayotopoulou EG; Müller AK; Börries M; Busch H; Hu G; Lev S
    Oncotarget; 2017 Jul; 8(28):45088-45104. PubMed ID: 28187446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cepharanthine sensitizes human triple negative breast cancer cells to chemotherapeutic agent epirubicin via inducing cofilin oxidation-mediated mitochondrial fission and apoptosis.
    Shen LW; Jiang XX; Li ZQ; Li J; Wang M; Jia GF; Ding X; Lei L; Gong QH; Gao N
    Acta Pharmacol Sin; 2022 Jan; 43(1):177-193. PubMed ID: 34294886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.